Start a conversation.
Open a case and write the genetics question naturally.
Functional Prototype · Validation Stage
From fragments
to understanding.
Somerilo is a genetics-focused AI-assisted case and consultation platform built around natural conversation, documents and evolving context.
AI prepares and organizes.
Human experts retain clinical authority.
THE CONTEXT CHALLENGE
A case rarely arrives
as a complete picture.
Conversation, clinical context, family information, reports and previous testing may arrive at different moments. Follow-up brings more information.
Connecting these fragments helps the developing case become coherent context.
THE FUNCTIONAL PROTOTYPE
Conversation and documents.
Part of the same case.
Natural text interaction, relevant documents and follow-up, with information that carries forward.
THE CONTINUING CASE
One case.
Evolving context.
Information can be added as the case develops — without restarting the conversation.
Explore a connection.
A natural message becomes part of the case.
SAME CASEEvolving
case context
case context
HOW SOMERILO WORKS TODAY
Begin naturally.
Keep the connection.
Add documents.
Optionally attach a document and send it with your message.
Ask follow-up questions.
Continue the conversation within the same case.
Keep the context evolving.
Add information or more documents later. Continue from the evolving case context.
HUMAN AUTHORITY
AI prepares and organizes.Human experts retain clinical authority.
AI supports organization and understanding. Qualified professionals retain responsibility for clinical interpretation, test decisions and care.
Read Validation & Trust
AI-assisted preparation
- Organize
information - Understand
documents - Maintain
evolving context - Clarify missing or
unclear information - Prepare concise
summaries
INSTITUTIONAL DESIGN DIRECTION
Simple to interact with.
Structured underneath.
The current experience is conversation, documents and follow-up. Deeper contextual and institutional structure remains a design direction being evaluated.
Current foundation
Continuing case information for genetics-focused conversation, document-aware interaction and follow-up.
Future direction · not current functionality
Structured information, evaluations, provenance, integrations and governance for institutional workflows.
For genetics laboratories, hospitals, healthcare organizations, clinical and innovation teams, and strategic partners exploring controlled validation.
Explore institutional depthPLATFORM & INTEGRATIONS · ROADMAP
Built as a core platform,
not a single interface.
Somerilo’s current functional prototype is built around natural conversation, documents, follow-up and evolving context. Its underlying platform architecture is being designed to support controlled distribution through professional AI ecosystems, enterprise APIs and healthcare integrations over time — while preserving defined data boundaries and human clinical authority.
DESIGNED FOR / ROADMAP
Professional AI channels
Controlled delivery into professional AI environments while maintaining explicit data boundaries and human oversight.
DESIGNED FOR / ROADMAP
Enterprise APIs
Secure programmatic interfaces and developer SDKs for institutional systems and private workflows.
DESIGNED FOR / ROADMAP
Private / regional deployment
Dedicated hosting and regionally isolated environments designed around organizational governance requirements.
DESIGNED FOR / ROADMAP
Healthcare interoperability
Standards-based interoperability including FHIR / SMART and healthcare enterprise integrations as capabilities mature.
Planned architecture direction — integrations and distribution channels are roadmap items, not current capabilities.
PRIVACY & DEPLOYMENT ARCHITECTURE
Different environments
require different data boundaries.
Somerilo is being designed with deployment boundaries in mind — from synthetic demonstrations to protected enterprise environments and, where appropriate in the future, dedicated or regionally controlled deployments. These are architecture and readiness directions, not claims of regulatory approval.
Public demonstrations use synthetic data and are not intended for clinical use.
CURRENT
Synthetic / Controlled Demonstration
Isolated demonstration environments operating solely on synthetic case materials for validation and workflow exploration.
FUTURE / PRODUCT DIRECTION
Professional & Protected Enterprise
Encrypted, tenant-isolated environments with organizational access controls and customer-managed data boundaries.
FUTURE / PRODUCT DIRECTION
Dedicated & Regulated Clinical Deployment
Dedicated or regionally hosted instances, subject to formal validation, governance, security readiness and appropriate regulatory approvals.
FOR HEALTHCARE ORGANIZATIONS
Three engagement pathways
as the platform evolves.
Whether evaluating Somerilo in a controlled pilot today or planning future institutional adoption, engagements are structured around clear operational and governance boundaries.
Current Primary Offer
Validation Pilot
Evaluate Somerilo in a defined, controlled genetics workflow with agreed scope, users and measures.
Roadmap
Professional / Team
A future pathway for qualified professionals and small teams as the product matures.
Future direction · No public subscriptions currently available.
Future Direction
Enterprise Clinical
For organizations that require deeper integration, governance, protected deployment and support.
Subject to productization, security maturity and governance requirements.
ENTERPRISE GOVERNANCE & COMPLIANCE
Clear governance and compliance responsibilities, defined contractually.
Enterprise engagements can be structured around customer-managed compliance responsibilities, Somerilo-assisted compliance enablement, or dedicated/private deployment arrangements. Scope, responsibilities, approvals and applicable requirements are defined contractually.
Customer-Managed ComplianceSomerilo-Assisted Readiness & Compliance SupportPrivate / Joint Enterprise Deployment
Commercial engagement and responsibility models, not regulatory certifications or legal advice. Regulatory, legal and clinical approvals remain subject to the applicable organization, jurisdiction and qualified authorities. Clinical authority and final decisions remain with qualified professionals.
CURRENT / VALIDATING / ROADMAP
A working core.
Evidence before expansion.
The distinction between what works today, what is being validated, and future roadmap directions is visually and operationally unambiguous.
Current
What works today
- Natural conversation
- Documents + contextual Q&A
- Follow-up
- Additional information and documents
- Evolving context
Validating
What we are validating
- Reliability
- Context retention reliability
- Boundary behavior
- Latency
- Cost
- Failure modes
- Usability
- Human review criteria
Roadmap
Roadmap / product direction
- Platform / API layer
- Privacy & Policy Gateway
- External distribution adapters
- Enterprise Protected deployment
- FHIR / SMART and enterprise integrations
GENETICS FIRST · FUTURE POSSIBILITY
Genetics first.
Designed with room to evolve.
Genetics is the present focus. Any extension into adjacent complex clinical domains would be controlled, evidence-led and subject to further validation.
Long-term direction — Somerilo does not currently serve multiple clinical domains.
Explore the visionOMAN-FIRST VALIDATION / PARTNERSHIP
Begin locally.
Build through evidence.
Start with controlled institutional validation in Oman. Paid pilots and commercialization depend on demonstrated value and viable delivery. GCC expansion represents the next regional direction, with selective international expansion considered as evidence, regulatory readiness and strategic fit mature.
Somerilo has a functional genetics-focused core, an Oman-first validation path, a privacy-aware enterprise architecture, and a planned multi-channel distribution strategy designed to extend the same core into professional AI ecosystems and healthcare enterprise environments over time.
- OmanInitial validation focus
- CommercializationSubject to pilot and buyer evidence
- GCCFuture expansion direction
Longer-term expansion will be evaluated across selected international markets, guided by evidence, regulatory readiness and strategic fit.
Explore the intended commercial modelCONTROLLED INSTITUTIONAL VALIDATION
Discuss a
Validation Pilot.
For genetics teams, laboratories, clinical organizations and innovation teams exploring controlled institutional validation.
Pilot / business inquiry
Business contact information only.
Checking inquiry availability…